- China
- /
- Medical Equipment
- /
- SZSE:300412
Zhejiang Canaan Technology Third Quarter 2024 Earnings: EPS: CN¥0.01 (vs CN¥0.024 in 3Q 2023)
Zhejiang Canaan Technology (SZSE:300412) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥297.8m (up 3.4% from 3Q 2023).
- Net income: CN¥3.13m (down 50% from 3Q 2023).
- Profit margin: 1.1% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses.
- EPS: CN¥0.01 (down from CN¥0.024 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zhejiang Canaan Technology shares are up 4.9% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Zhejiang Canaan Technology (1 is a bit concerning) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Zhejiang Canaan Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300412
Zhejiang Canaan Technology
Engages in the research and development, production, and sale of pharmaceutical equipment in China and internationally.
Mediocre balance sheet and slightly overvalued.